General information

Location

11 December 2014 – NYAM Presidents Gallery
12 December 2014 – NYAM Room 20

Jointly provided by:

The Mount Sinai Liver Cancer Program Icahn School of Medicine at Mount Sinai and the International Liver Cancer Association (ILCA)

Programme directors

Josep M. Llovet, MD, Professor of Medicine, Director, Mount Sinai Liver Cancer Program
Scott Friedman, MD, Professor of Medicine, Dean for Therapeutic Discovery
Myron Schwartz, MD, Professor of Surgery, Director of Liver Surgery, Transplant Institute

Target audience

Hepatologists, gastroenterologist, oncologists, surgeons, radiologist, pathologists and basic scientists interested in liver cancer

Activity description

This conference will assemble multidisciplinary experts on hepatocellular carcinoma from the Mount Sinai Liver Cancer Program and two outstanding invited lecturers. The meeting is intended to provide a summary of the state-of ¬the-art knowledge of the pathogenesis and clinical management of hepatocellular carcinoma, and the research conducted in Mount Sinai. In addition, the participants will be exposed to the clinical management in HCC and critical sessions discussing clinical trials.

Activity learning objectives

  • Review recent developments in the genomics of liver cancer and their therapeutic implications.
  • Summarise current indications for resection and transplantation vis-a-vis medical and nonsurgical locoregional modalities.
  • Review the current management of intrahepatic cholangiocarcinoma and the opportunities of improvement in the near future.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of International Liver Cancer Association (ILCA) and The Icahn School of Medicine at Mount Sinai is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Icahn School of Medicine at Mount Sinai designates this live activity for a maximum of 12.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Verification of Attendance

Verification of attendance will be provided to all professionals.

General information

8:30 – 9:00 Registration
9:00 – 9:10 Welcome and Opening
Steven Burakoff, MD, Director, Tisch Cancer Institute
9:10 – 9:40 Achievements of Mount Sinai Liver Cancer Program 05-14
Josep M. Llovet, MD, Mount Sinai Liver Cancer Program
Director’s Perspective
9:40 – 10:10 From Liver Fibrosis to Cancer
Scott Friedman, MD, Mount Sinai Liver Cancer Program
10:10 – 10:40 Overview of Management of HCC and Therapeutic Challenges
Josep M. Llovet, MD, Mt Sinai Liver Cancer Program
10:40 – 11:10 Surgical Management of HCC and ICC
Myron Schwartz, MD, Mount Sinai Liver Cancer Program
11:10 – 11:30 Coffee Break
11:30 –13:00 Practical Session
Coordinators: Myron Schwartz, MD, and Charissa Chang, MD, Mount Sinai Liver Cancer Program
13:00 – 13:40 Lunch
13:40 – 15:00 Prevention and Staging of HCC
Chair: Scott Friedman, MD, Mount Sinai Liver Cancer Program
13:40 – 14:00 Impact of Novel Anti-Viral Therapies in the Development of HCC
Ponni Perumalswami, MD, Mount Sinai Liver Cancer Program
14:00 – 14:30 Pathological Markers Defining HCC, ICC and Mixed Tumours
Swan Thung, MD, Mount Sinai Liver Cancer Program
14:30 – 14:50 Assessment of Response after TACE and Systemic Therapies
Bachir Taouli, MD, Mount Sinai Liver Cancer Program
15:00 –15:20 Coffee Break
15:20 –17:00 Management of Liver Cancer
Chair: Josep M. Llovet, MD, Mt Sinai Liver Cancer Program
15:20 – 15:50 Overview of Transplant Programme
Sander Florman, MD, Mount Sinai Liver Cancer Program
15:50 – 16:10 Management of Intermediate HCC
Edward Kim, MD, Mount Sinai Liver Cancer Program
16:10 – 16:40 Advanced HCC: RCT in HCC after Sorafenib Success: What’s next?
Josep M. Llovet, MD, Mount Sinai Liver Cancer Program
16:40 – 17:00 Emerging Drugs for HCC and ICC
Augusto Villanueva, MD
9:00 – 11:00 Retreat on Clinical Trials – Liver Cancer Programme
Chairs: Josep M. Llovet, MD, and Myron Schwartz, MD, Mount Sinai Liver Cancer Program
9:00 – 9:15 Early HCC in the Adjuvant Setting
Charissa Chang, MD, Mount Sinai Liver Cancer Program
9:15 – 9:30 Early HCC and Prevention Recurrence after Transplantation
Sander Florman, MD, Mount Sinai Liver Cancer Program
9:30 – 9:45 Intermediate HCC
Edward Kim, MD, Mount Sinai Liver Cancer Program
9:45 – 10:15 Advanced HCC, First Line
Radioembolization
Myron Schwartz, MD, Mount Sinai Liver Cancer Program
Molecular therapies
Max Sung, MD, Mount Sinai Liver Cancer Program
10:15 – 10:45 Advanced HCC, Second Line
Molecular therapies
Charissa Chang, MD, and Celina Ang, MD, Mount Sinai Liver Cancer Program
10:45 – 11:00 Discussion of Flow-Chart for Inclusion of Patients in HCC Trials
11:00 –11:20 Coffee Break
11:30 –13:00 Practical Session
Coordinators: Myron Schwartz, MD and Charissa Chang, MD Mount Sinai Liver Cancer Program
13:00 – 13:40 Lunch
13:40 –14:10 State-of-the-Art Lecture: Translating Advances in Molecular Therapies from Oncology into the HCC Field
Richard Finn, MD, UCLA Medical Center
14:10 –15:30 Novel Drivers of Hepatocarcinogenesis
Chair: Sam Waxman, MD, Mount Sinai Liver Cancer Program
14:10 –14:30 Experimental Models for Driver Identification in HCC
Kirsten Sadler, PhD, Mount Sinai Liver Cancer Program
14:30 –14:50 Role of Stellate Cells in HCC Development
Amaia Lujambio, MD
14:50 – 15:10 Molecular Classification of HCC
Yujin Hoshida, MD, PhD, Mount Sinai Liver Cancer Program
15:10 – 15:30 Discovery of Novel Targets for Treating ICC
Daniela Sia, PhD, Mount Sinai Liver Cancer Program
15:30 Closing Remarks

The programme of the ILCA School 2014 is subject to change.